Aprocitentan: New insights

Front Cardiovasc Med. 2022 Dec 22:9:1093406. doi: 10.3389/fcvm.2022.1093406. eCollection 2022.

Fahimeh Varzideh^{1

2}, Urna Kansakar^{1

2}, Stanislovas S Jankauskas^{1

2}, Gaetano Santulli^{1

2}

¹ Department of Medicine, Division of Cardiology, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, New York, NY, United States.
² Department of Molecular Pharmacology, Einstein Institute for Aging Research, Einstein Institute for Neuroimmunology and Inflammation, Fleischer Institute for Diabetes and Metabolism (FIDAM), Albert Einstein College of Medicine, New York, NY, United States.

No abstract available

Keywords: ACT-132577; PRECISION; aprocitentan; blood pressure; clinical trial; endothelin; hypertension; resistant hypertension.

Grants and funding